Biogen 3Q Revenues: $2.8 billion (-18%) 3Q Earnings: $318 million (-55%) YTD Revenues: $8.2 billion (-22%) YTD Earnings: $1.7 billion (-53%) Comments: Multiple sclerosis (MS) revenue, including royalties on sales of OCREVUS, were $1.8 billion in the quarter, down 19%. SPINRAZA revenue was $444 million, down 10%. ADUHELM revenue was $0.3 million. In June 2021 the U.S. FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 20...